Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $55.82 USD
Change Today +1.38 / 2.53%
Volume 617.7K
KITE On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Arie S. Belldegrun M.D., FACS

Founder, Executive Chairman, Chief Executive Officer and President,Kite Pharma, Inc.
AgeTotal Calculated CompensationThis person is connected to 46 board members in 6 different organizations across 10 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. Arie S. Belldegrun, M.D., FACS founded Kite Pharma, Inc. in 2009 and has been its Chief Executive Officer and President since April 2, 2014. Dr. Belldegrun served as Partner at Two River Group Holdings LLC. He serves as the Chief of Division of Urological Oncology. He serves as a Professor and holds the Carol and Roy Doumani Chair in Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) since 1996, whose faculty ...

Read Full Background

Corporate Headquarters*

2225 Colorado Avenue
Santa Monica, California 90404

United States

Phone: 310-824-9999
Fax: --

Board Members Memberships*

Partner, Chairman, and a Member of Advisory Board
Non-Executive Chairman of the Board
Founder, Executive Chairman, Chief Executive Officer and President
Director and Vice Chairman of Science & Technology Committee


Unknown/Other Education
Weizmann Institute Of Science
Hebrew University Faculty of Medicine
Hebrew University Faculty of Medicine

Other Affiliations*

Annual Compensation*

Total Annual Compensation$387,225

Stock Options*

All Other Compensation$34,149
Unexercisable Options139,200
Total Number of Options139,200

Total Compensation*

Total Annual Cash Compensation$721,374
Total Short Term Compensation$387,225
Other Long Term Compensation$34,149
Total Calculated Compensation$16,165,793
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KITE:US $55.82 USD +1.38


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KITE PHARMA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at